Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: Quality of life and surrogate markers of activity

Anti-Cancer Drugs

Volumn 18, Issue 8, 2007, Pages 949-954

  Curigliano, Giuseppe ^a   De Braud, Filippo ^a   Teresa Sandri, Maria ^a   Renne, Giuseppe ^a   Zorzino, Laura ^a   Scardino, Epifanio ^a   Rocco, Bernardo ^a   Spitaleri, Gianluca ^a   De Pas, Tommaso ^a   Noberasco, Cristina ^a   Nolè, Franco ^a   Verweij, Fabrizio ^a   Matei, Victor ^a   De Cobelli, Ottavio ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Extracellular domain; Gefitinib; HER2; Phase II study; Prostate cancer; Serum epidermal growth factor receptor

Indexed keywords

BICALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUTAMIDE; GEFITINIB; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; ENDOCRINE SYSTEM; FATIGUE; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SIDE EFFECT; SKIN NECROSIS; SKIN ULCER; TREATMENT RESPONSE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENDPOINT DETERMINATION; GENES, ERBB-1; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 34547697012     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328136c162     Document Type: Article

References (36)

1. American Cancer Society: Prostate cancer statistics. http://www.cancer. org/docroot/home/index.asp.
2. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171 (2 Pt 1):679-683.
3. Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157:1731-1735.
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-refractory prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14:1756-1764.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
6. Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001; 58 (2 Suppl 1):S115-S122.
7. McKeehan WL, Adams PS, Rosser MP. Direct mitogenic effects of insulin epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin but not androgen on normal rat prostate epithelial cells in serum free primary cell culture. Cancer Res 1984; 44:1998-2010.
8. Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer 1986; 54:265-269.
9. Bradley SJ, Garfinkle E, Walker R, Salem R, Chen LB, Steele G Jr. Increased expression of the epidermal growth factor receptor on human colon carcinoma cells. Arch Surg 1986; 121:1242-1247.
10. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799.
11. Lorenzo GD, Bianco R, Tortora G, Ciardiello F. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2003; 2:50-57.
12. Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, Vicentini C, et al. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 2005; 115:630-640.
13. Tillotson JK, Rose DP. Density-dependent regulation of epidermal growth factor receptor expression in DU 145 prostate cancer cells. Prostate 1991; 19:53-61.
14. Weichselbaum RR, Dunphy EJ, Beckett MA, Tybor AG, Moran WJ, Goldman ME, et al. Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck 1989; 11:437-442.
15. Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten CS, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 2002; 1:122-128.
16. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumour xenographs is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGF receptor tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
17. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002; 8:3870-3876.
18. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
19. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14:922-930.
20. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-3825.
21. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
22. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
23. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
24. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-794.
25. Hudelist G, Kostler WJ, Gschwantler-Kaulich D, Czerwenka K, Kubista E, Muller R. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur J Cancer 2006; 42:186-192.
26. Gasparini G, Sarmiento R, Amici S, Longo R, Gattuso D, Zancan M, Gion M. Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Ann Oncol 2005; 16:1867-1873.
27. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10 (18 Pt 1):6006-6012.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000; 92:205-216.
29. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50:920-928.
30. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
31. Zee B, Melnychuk D, Dancey J, Eisenhauer E. Design of phase II clinical trials incorporating response and early progression. Control Clin Trials 1996; 12:S85 (abstr 80).
32. Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157:1731-1735.
33. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 1993; 11:1566-1572.
34. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995; 76:1428-1434.
35. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23:455-460.
36. Jose D, Debes JD, Donald J, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351:1488-1490.